

Anti-Tau [pS199] Rabbit Polyclonal Antibody Ref. 4BDX-1502S

Biomolecule

Anti-Tau [pS199] rabbit polyclonal antibody

Size 40 μl

Formulation

Rabbit serum diluted in glycerol with 0.05% sodium azide

Storage +4°C / -20°C

Immunogen Peptide

Specificity

Anti-Tau phosphorylated at serine 199

Cross-reactivity Human, Mouse, Rat

Applications WB, IHC, IF

• Preparation

This polyserum was obtained by immunizing a rabbit with a 12 amino acid peptide containing the phosphorylated serine 199 (SGYSSPGSPGT). The phosphorylated threonine is underlined.

• Specificity

Determined by its ability to recognise human Tau phosphorylated at serine 199.

• <u>Storage</u>

Store at +4°C for short term use (1-2 weeks) - Store at -20°C for long term use.

• Applications

Recommended concentration of use are:

Western-blot: 1:4000 in Tris HCl pH 8.0 Tween-20 0.05% and 5% dry skimmed milk (working with cell and tissue).

IHC /IF: 1:200 in PBS with 5% BSA (working with cell, frozen and paraffin embedded tissue).

General information



Tau proteins are encoded by a single gene MAPT (Gene ID: 4137). They belong to the family of microtubule-associated proteins. Neurofibrillary degeneration is characterized by an accumulation of fibrils made of hyper and abnormally phosphorylated Tau proteins. The Tau phosphorylation at serine 199 is an indicator of the early step of neurofibrillary degeneration. On human brain tissue or in animal models of tauopathies, this antibody detects specifically neurons in neurofibrillary degeneration. The serine 199 is phosphorylated by the following kinases: CDK5 (cyclin dependent kinase 5), CK2 (casein kinase 2), PKA (protein kinase A), GSK3 (glycogen synthase kinase 3), ERK/MAPK (mitogen activated kinases) and MARK (Microtubule-associated protein/microtubule affinity-regulating kinase).


<u>References</u>

Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D and Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 9(4):397-405.


Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E , Schraen-Maschke S, and Buee L (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert review of proteomics 5:207–224.

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P. New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiol Dis. 2019 Sep;129:217-233.

Application examples




Western-blotting of Tau at phosphoserine 199 in SY5Y Tau inducible expressing cells (1,2: non induced ; 3,4: induced)



Immunohistochemistry of neurofibrillary degeneration in Alzheimer brain tissue

TO PLACE AN ORDER



Immunofluorescence of hyperphosphorylated Tau at phospho-serine 199 in mouse Thy-Tau22



commercial@4biodx.com



(33) 320 622 079



www.4biodx.com



SPQI SAS 82 rue Jeanne d'Arc, 59000 Lille, France

RCS Lille Metropole 820 961 514 – Code APE 7219Z VAT : FR 40 820 961 514 000 24